Tous les communiqués de presse

all press releases
  • Legend
  • corporate
  • finance
  • sciences
  • PFIC Annual information Statement

    read more download
  • Servier and Pfizer announce FDA clearance of IND application for UCART19 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia

    9 March 2017 – Servier, together with Pfizer Inc. (NYSE:PFE) and Cellectis (Alternext: ALCLS; Nasdaq: CLLS), announced today that the U.S. Food and Drug Administration (FDA) has granted Servier with an Investigational New Drug (IND) clearance to proceed in the U.S. with the clinical development of UCART19, an allogeneic, gene-edited cellular therapy candidate to treat relapsed/refractory acute lymphoblastic leukemia.

    read more
  • Five Additional Leading Physicians to Join Cellectis Clinical Advisory Board

    New Board Members Include Hematology Experts Catherine Bollard, Hervé Dombret, Ola Landgren, Marcela Maus & Dietger Niederweiser   March 7, 2017 – New York (N.Y.) – Cellectis (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), today announced five new leading experts will join the Company’s Clinical Advisory Board (CAB) in 2017 from the fields of hematologic malignancies, immunotherapy, immunology, stem cell transplantation. The CAB serves as a strategic resource to Cellectis as the Company enters the clinical development of allogeneic CAR T immunotherapies, led by its wholly owned product candidate, UCART123.

    read more download
  • Cellectis Reports 4th Quarter and Full Year 2016 Financial Results

    New York, N.Y. – March 6, 2017 – Cellectis S.A. (Alternext: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), today announced its results for the three-month period ended December 31, 2016 and for the year ended December 31, 2016.

    read more download
  • Corporate Presentation February 2017

    read more download

Pages